The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study
Abstract
Background Our understanding of the pathogenic role of IgE in atopic dermatitis is incomplete. We asked whether blocking free IgE would alter the course of the disease. Patients and methods We administered either omalizumab, a humanized monoclonal mouse antibody against IgE, or placebo subcutaneously for 16 weeks to 20 atopic dermatitis patients and measured immunological and clinical disease parameters. Results Omalizumab (I) reduced free serum IgE, (II) lowered surface IgE and FcɛRI expression on different peripheral blood mononuclear cells, (III) reduced the saturation of FcɛRI with IgE, (IV) increased the number of free FcɛRI and (V) lowered the number of IgE+, but not of FcɛRI+ cells in skin. The in vivo relevance of these results is evidenced by the increase in the threshold allergen concentration required to give a type I hypersensitivity reaction in the titrated skin test. While not significantly altering the clinical disease parameters, omalizumab treatment led to an improvement of the atopy patch test results in single patients, i.e. an eczematous reaction upon epicutaneous allergen challenge. Conclusions The interference with immediate and delayed type skin tests may imply that a therapeutic benefit of omalizumab treatment, if present at all, would be seen in patients with acute rather than chronic forms of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“strategies aimed at depleting IgE with the anti-IgE biologic omalizumab failed to show convincing results in proof-of-concept studies and single cases107,108.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [107]
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,597
Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
Leung, D. Y. M., & Bieber, T. R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12193-9 · Cited by 1,164
Cytokine modulation of atopic dermatitis filaggrin skin expression
Howell, M. D., Kim, B. E., Gao, P., Grant, A. V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L. A., Barnes, K. C., & Leung, D. Y. M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.031 · Cited by 1,084
Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M., & TOKURA, Y. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.111 · Cited by 680
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M. D., Chung, K. F., Bao, W., FowlerTaylor, A., Matthews, J. G., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 644
New developments in FcεRI regulation, function and inhibition
Kraft, S., & Kinet, J. (2007) · Nature reviews. Immunology · doi:10.1038/nri2072 · Cited by 580
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S. T., Casale, T. B., Wenzel, S. E., Bousquet, J. J., Deniz, Y. M., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 468
Omalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A. G., & Saini, S. S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456
Cited by
Sorted by citations
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,305
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M. R., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 888
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Guttman‐Yassky, E., Bissonnette, R., Ungar, B., Suárez‐Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y. D., Xu, H., Peng, X., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 715
Metadata
- Authors
- Heil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G.
- Affiliations
- Medical University of Vienna (AT)
- Johannes Gutenberg University Mainz (DE)
- Venue
- JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Publisher
- Wiley
- Published
- 2010-11-25
- Volume
- 8
- Issue
- 12
- Pages
- 990-998
- ISSN
- 1610-0379 (ISSN-L)
- 1610-0387
- OpenAlex
- W1512818159
- Cited by
- 197
- References
- 38
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 3 · 2023: 10 · 2022: 6 · 2021: 14 · 2020: 10 · 2019: 14 · 2018: 12 · 2017: 19 · 2016: 24 · 2015: 24 · 2014: 13 · 2013: 15 · 2012: 16
- FWCI
- 13.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JDDG Journal der Deutschen Dermatologischen Gesellschaft (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- omalizumab, atopic dermatitis, IgE, FcεRI, immediate hypersensitivity, atopy patch test, chronic atopic dermatitis
- MeSH terms
- Omalizumab, Adolescent, Adult, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Immunoglobulin E, Injections, Subcutaneous, Male, Middle Aged, Pilot Projects, Skin Tests, Placebo Effect, Treatment Outcome, Anti-Allergic Agents, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
